Cargando…

Prognostic relevance of tumor‑infiltrating lymphocytes in residual tumor tissue from patients with triple‑negative breast cancer following neoadjuvant chemotherapy: A systematic review and meta‑analysis

Further adjuvant chemotherapy treatment can provide benefits to certain patients with triple-negative breast cancer (TNBC) that fail to achieve pathological complete response (pCR) after the administration of a neoadjuvant chemotherapy (NAC) regimen. However, biomarkers suitable for identifying pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Bo, Zhang, Ziran, Wang, Chaoxian, Lv, Xiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472026/ https://www.ncbi.nlm.nih.gov/pubmed/37664648 http://dx.doi.org/10.3892/ol.2023.14028

Ejemplares similares

Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: da Silva, Jesse Lopes, et al.
Publicado: (2021)

Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy
por: Bai, Yu-Ge, et al.
Publicado: (2020)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

Prognostic significance of tumor-infiltrating CD8(+) and FOXP3(+) lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study
por: Miyashita, Minoru, et al.
Publicado: (2015)

Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy
por: Herrero-Vicent, Carmen, et al.
Publicado: (2017)

Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Ki67 Index Changes and Tumor-Infiltrating Lymphocyte Levels Impact the Prognosis of Triple-Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
por: Wang, Yihua, et al.
Publicado: (2021)

Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers
por: Tian, Tian, et al.
Publicado: (2016)

Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
por: Li, Zhijun, et al.
Publicado: (2023)

Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast
por: Jamiyan, Tsengelmaa, et al.
Publicado: (2020)

Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden
por: Asano, Yuka, et al.
Publicado: (2017)

SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival
por: Wang, Ruo-Xi, et al.
Publicado: (2022)

Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers
por: Ruan, Miao, et al.
Publicado: (2018)

Prognostic Implications of the Residual Tumor Microenvironment after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients without Pathological Complete Response
por: Lejeune, Marylène, et al.
Publicado: (2023)

Prognostic value of tumor-infiltrating B lymphocytes and plasma cells in triple-negative breast cancer
por: Kuroda, Hajime, et al.
Publicado: (2021)

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer
por: Loi, Sherene, et al.
Publicado: (2022)

Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial
por: Kolberg-Liedtke, Cornelia, et al.
Publicado: (2022)

The Impact of Tumor Infiltrating Lymphocytes Densities and Ki67 Index on Residual Breast Cancer Burden following Neoadjuvant Chemotherapy
por: Elmahs, Aya, et al.
Publicado: (2022)

Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer
por: Cavallone, Luca, et al.
Publicado: (2020)

Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: A meta-analysis
por: Li, Shiqi, et al.
Publicado: (2022)

Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis
por: Gao, Guoxuan, et al.
Publicado: (2020)

Tumor microenvironment in triple-negative breast cancer: the correlation of tumor-associated macrophages and tumor-infiltrating lymphocytes
por: Kuroda, H., et al.
Publicado: (2021)

Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma
por: Vermeulen, Jeroen F., et al.
Publicado: (2017)

Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting
por: García-Teijido, Paula, et al.
Publicado: (2016)

Immunotyping of tumor-infiltrating lymphocytes in triple-negative breast cancer and genetic characterization
por: Gomez-Macias, Gabriela Sofia, et al.
Publicado: (2020)

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030
por: Parsons, Heather A., et al.
Publicado: (2023)

A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer
por: Miglietta, Federica, et al.
Publicado: (2023)

Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
por: Ding, Feng, et al.
Publicado: (2022)

Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy
por: Giacchetti, Sylvie, et al.
Publicado: (2022)

Prognostic Significance of Lymphocyte Infiltrate Localization in Triple-Negative Breast Cancer
por: Čeprnja, Toni, et al.
Publicado: (2022)

Relevance of tumor-infiltrating lymphocytes in breast cancer
por: Dushyanthen, Sathana, et al.
Publicado: (2015)

The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy
por: Li, Ruonan, et al.
Publicado: (2023)

No Impact of Smoking Status on Breast Cancer Tumor Infiltrating Lymphocytes, Response to Neoadjuvant Chemotherapy and Prognosis
por: Simon, Vanille, et al.
Publicado: (2020)

Effects of tumor-infiltrating lymphocytes on nonresponse rate of neoadjuvant chemotherapy in patients with invasive breast cancer
por: Qian, Xiao-Long, et al.
Publicado: (2023)

Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy
por: Yang, Xia, et al.
Publicado: (2018)

Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS
por: Wang, Qiong, et al.
Publicado: (2020)

Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
por: Oner, Gizem, et al.
Publicado: (2021)

T-Cell Immunoglobulin Mucin 3 Expression on Tumor Infiltrating Lymphocytes as a Positive Prognosticator in Triple-Negative Breast Cancer
por: Byun, Kyung Do, et al.
Publicado: (2018)

Systemic immune reaction in axillary lymph nodes adds to tumor-infiltrating lymphocytes in triple-negative breast cancer prognostication
por: Liu, Fangfang, et al.
Publicado: (2021)

PERCEPTION Trial protocol: Comparison of predictive and prognostic capacities of neutrophil, lymphocyte, and platelet counts and tumor-infiltrating lymphocytes in triple negative breast cancer
por: Lusho, Sejdi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i4u2pcprdlpgn5rc3uos3au9ti